Concentric Pharma Advertising

Concentric Named Professional Agency of Record for Discovery Labs' SURFAXIN(R)

Published in Medical Letter on the CDC and FDA, September 21st, 2008

Concentric Pharma Advertising, one of the fastest growing marketing agencies in the healthcare field, has been named agency of record by Discovery Labs for SURFAXIN(R) (lucinactant), an investigational drug being reviewed by the Food and Drug Administration for the treatment of respiratory distress syndrome (RDS) in newborns.

"We selected Concentric for this assignment because the company's strategic insight and creative vision best captured the essence of the SURFAXIN brand," said John Wilson, vice president of sales and marketing at Discovery, adding that the agency's in-depth knowledge of neonatology and acute RDS in premature infants also played a significant part...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2008-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry